Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company
Four new members enhance independence and diversity of Board of DirectorsAlvotech is dual listed on NASDAQ in the U.S. and...
Pharmaceutical
Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company
Four new members enhance independence and diversity of Board of DirectorsAlvotech (NASDAQ and First North Growth Market: ALVO), a global...
TFF Pharmaceuticals Expands R&D Operations with New Austin Facility
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly...
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically...
Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million...
OraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA
BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home...
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular...
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland,...
BUSINESS UPDATE
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals...
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths...
Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneConfirmed low levels of free docetaxel...
Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
How AI Solves Pharma’s Data Disconnect
By Rohit Vashisht Competition in the pharmaceutical industry is driving a race to collect the most data and build the...
Digital Technologies In The Supply Chain
By Jonathan Wilkins Errors in the pharmaceutical supply chain can lead to late delivery, increased costs and poor-quality products, which...